We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing evorpacept (ALX148) as a foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 03:58:33 UTC

Jan 10, 2022

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

Jan 04, 2022

ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 12, 2021

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

Twitter

ALX Oncology today provided a corporate update and highlighted key milestones anticipated in 2022: https://bit.ly/31GnHHs

ALX Oncology will virtually present a company overview at the 40th Annual #JPM22 Healthcare Conference on Tuesday, January 11 at 10:30 am ET. Find the live webcast here: https://bit.ly/3HCR4tP

ALX Oncology announced initial data from ASPEN-02, demonstrating safety and preliminary activity in patients with #myelodysplasticsyndrome at the 63rd @ASH_hematology Annual Meeting https://bit.ly/3oL0Jb1

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE